先天性心脏病手术中使用脱细胞牛心包补片行主动脉瓣修复术的结果
回顾性分析40例先天性主动脉瓣病变患者使用CardioCel®补片行主动脉瓣重建,中位随访22个月,23%发生事件(死亡1例、再手术8例),免于再手术或死亡概率12、24、36个月分别为97±3%、76±9%、57±12%,结论为3年内结果不理想。
要点
- 40例先天性主动脉瓣病变患者使用脱细胞牛心包补片行主动脉瓣重建,中位年龄9岁。
- 随访期间23%发生事件,其中死亡1例(2.5%)、再手术8例(20%)。
- 免于再手术或死亡概率在12、24、36个月分别为97±3%、76±9%、57±12%。
核心结论
- 先天性主动脉瓣疾病患者使用脱细胞牛心包补片行主动脉瓣重建,在3年随访内结果不理想。
研究设计与样本
- 回顾性分析2014年2月至2016年8月连续40例使用CardioCel®补片行主动脉瓣重建的先天性心脏病患者资料。
- 患者手术时中位年龄9(2-34)岁,其中18例小于7岁。
- 26例初始表现为主动脉瓣关闭不全,14例为狭窄。
- 临床和超声心动图数据随访至2017年8月,中位术后随访22(6-42)个月。
主要发现
- 40例中9例(23%)随访期间发生事件,包括死亡1例(2.5%)和再手术8例(20%)。
- 再手术原因:狭窄3例(37.5%)、关闭不全4例(50%)、主动脉瓣心内膜炎1例(12.5%)。
- 其余31例中,2例计划再手术(主动脉瓣狭窄1例、关闭不全1例),9例主动脉瓣功能恶化伴中度关闭不全。
- 免于再手术或死亡概率在12、24、36个月分别为97±3%、76±9%、57±12%。
- 免于复合终点(死亡/再手术/中度主动脉瓣功能障碍)概率在12、24、36个月分别为92±5%、55±9%、28±9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The search for an optimal patch material for aortic valve reconstruction (AVR) is an ongoing challenge. In this study, we report our experience of AVR using decellularized bovine pericardial patch material in congenital heart surgery. METHODS: Data of 40 consecutive patients who underwent AVR using the CardioCel® patch (Admedus Regen Pty Ltd, Perth, WA, Australia) between February 2014 and August 2016 were retrospectively reviewed. The median age of the patients at operation was 9 (2-34) years, and 18 patients were younger than 7 years. Twenty-six patients initially presented with aortic valve insufficiency (AI) and 14 with stenosis. Clinical and echocardiographic data were available until August 2017 for a median postoperative follow-up (FU) of 22 (6-42) months. RESULTS: Nine of 40 (23%) patients experienced an event during FU (death: n = 1, 2.5%; reoperation: n = 8, 20%). Overall, the probability of freedom from reoperation or death was 97 ± 3%, 76 ± 9% and 57 ± 12% at 12, 24 and 36 months of FU, respectively. Reason for reoperation was stenosis in 3 (37.5%) patients, insufficiency in 4 (50%) patients and 1 (12.5%) patient was diagnosed with aortic valve endocarditis. Of the remaining 31 patients, 2 patients are scheduled for reoperation (aortic valve stenosis: n = 1 and AI: n = 1) and 9 patients exhibit worsening of aortic valve function with moderate AI. Freedom from developing combined end point [death/reoperation/moderate degree of aortic valve dysfunction (aortic valve stenosis, AI)] after AVR was 92 ± 5%, 55 ± 9% and 28 ± 9% at 12, 24 and 36 months, respectively. CONCLUSIONS: AVR using decellularized bovine pericardial patch material in patients with congenital aortic valve disease show unsatisfactory results within the first 3 years of FU.
引用
- Nordmeyer S, Murin P, Schulz A, et al. Results of aortic valve repair using decellularized bovine pericardium in congenital surgery. Eur J Cardiothorac Surg. 2018. PMID: 29718178. doi:10.1093/ejcts/ezy181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。